New study tests which drug combo best protects kidneys in hypertensive patients

NCT ID NCT07223502

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial compares two treatments for people with high blood pressure and chronic kidney disease: finerenone versus a fixed-dose combination of torsemide and spironolactone. The study will enroll 30 adults to see which approach better lowers blood pressure, reduces protein in urine, and keeps potassium levels safe. The goal is to find a more effective way to manage both conditions together.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
finerenone and a fixed-dose combination of extended-release torsemide and spironolactone
What this could lead to
If this trial succeeds, it could point toward a more effective treatment option for managing high blood pressure and kidney disease with fewer side effects.
What could go wrong
This is a small early-phase trial with only 30 participants, so results may not apply to everyone. The study compares two existing drugs, so no breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Sarfez Pharmaceuticals, Inc.

    RECRUITING

    Vienna, Virginia, 22182, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.